Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease

Philip S. J. Weston¹*¹, Teresa Poole¹², Jennifer M. Nicholas¹², Nicolas Toussaint¹³, Ivor J. A. Simpson¹³, Marc Modat¹⁴, Natalie S. Ryan¹, Yuying Liang¹, Martin N. Rosser¹, Jonathan M. Schott¹, Sebastien Ourselin¹⁴, Hui Zhang⁵ and Nick C. Fox¹

Abstract

Background: There is increasing interest in improving understanding of the timing and nature of early neurodegeneration in Alzheimer’s disease (AD) and developing methods to measure this in vivo. Autosomal dominant familial Alzheimer’s disease (FAD) provides the opportunity for investigation of presymptomatic change. We assessed early microstructural breakdown of cortical grey matter in FAD with diffusion-weighted MRI.

Methods: Diffusion-weighted and T1-weighed MRI were acquired in 38 FAD mutation carriers (17 symptomatic, 21 presymptomatic) and 39 controls. Mean diffusivity (MD) was calculated for six cortical regions previously identified as being particularly vulnerable to FAD-related neurodegeneration. Linear regression compared MD between symptomatic and presymptomatic carriers and controls, adjusting for age and sex. Spearman coefficients assessed associations between cortical MD and cortical thickness. Spearman coefficients also assessed associations between cortical MD and estimated years to/from onset (EYO). Across mutation carriers, linear regression assessed associations between MD and EYO, adjusting for cortical thickness.

Results: Compared with controls, cortical MD was higher in symptomatic mutation carriers (mean ± SD CDR = 0.88 ± 0.39) for all six regions (p < 0.001). In late presymptomatic carriers (within 8.1 years of predicted symptom onset), MD was higher in the precuneus (p = 0.04) and inferior parietal cortex (p = 0.003) compared with controls. Across all presymptomatic carriers, MD in the precuneus correlated with EYO (p = 0.04). Across all mutation carriers, there was strong evidence (p < 0.001) of association between MD and cortical thickness in all regions except entorhinal cortex. After adjusting for cortical thickness, there remained an association (p < 0.05) in mutation carriers between MD and EYO in all regions except entorhinal cortex.

Conclusions: Cortical MD measurement detects microstructural breakdown in presymptomatic FAD and correlates with proximity to symptom onset independently of cortical thickness. Cortical MD may thus be a feasible biomarker of early AD-related neurodegeneration, offering additional/complementary information to conventional MRI measures.

Keywords: Alzheimer’s disease, Familial, Autosomal dominant, Presymptomatic, MRI, Diffusion, Mean diffusivity, Cerebral cortex
Background
In Alzheimer’s disease (AD), it has become increasingly important to understand the timing and nature of neurodegeneration and to develop sensitive methods for its detection and tracking. Of particular interest are the changes that characterise very early disease prior to the onset of clinical symptoms, as targeting treatments at this stage, before significant irreversible neuronal loss, may provide the greatest chance of success [1].

Autosomal dominant familial AD (FAD) shares many features—pathologically, radiologically and clinically—with the more common sporadic form of disease [2]. Unlike sporadic disease, FAD mutation carriers have relatively predictable ages at symptom onset based on family history [3], facilitating the prospective study of asymptomatic individuals prior to cognitive decline.

Early neurodegeneration involving cortical grey matter is a recognised feature of both sporadic and familial AD, with structural MRI identifying similar characteristic patterns of macrostructural loss within the cerebral cortex [4, 5]. Such cortical thinning predates symptom onset.

Diffusion-weighted imaging (DWI) allows assessment of changes at the microscopic level, with neuronal loss and the breakdown of microstructural barriers, such as myelin, cell membranes and intracellular organelles, resulting in a measurable difference in the diffusion of water molecules [6]. Measurement of such changes may provide additional and/or complementary information to conventional T1-weighted imaging, with studies suggesting that DWI changes may be more predictive of early progressive cognitive change than macrostructural atrophy [7, 8]. While most DWI studies in AD have focused on white matter [7, 9–11], it would follow, given the known early involvement of cortical grey matter [12], that measurement of microstructural DWI changes in the cortex could prove to be valuable in detecting and better characterising early neuronal breakdown. Grey matter changes have been found to be more closely related to clinical decline than those in white matter [13].

In AD, DWI measures of cortical grey matter have been found to differ between groups of individuals with amnestic MCI who do and do not go on to progress to AD dementia [8]. However, the ability of DWI to detect presymptomatic cortical changes, and their association with proximity to symptom onset, remains uncertain. It is also unclear whether cortical DWI metrics provide any additional information over and above that given by measurement of cortical thickness.

We used DWI to measure mean diffusivity (MD) in a group of FAD mutation carriers and non-carrier controls. MD is a DWI metric that increases with microstructural breakdown. It assesses diffusion in all directions and is therefore particularly suited to assessing grey matter, where diffusion is isotropic [14]. We hypothesised that cortical MD increases presymptomatically in FAD and correlates with proximity to symptom onset. Moreover, we aimed to assess the relationship between cortical MD and cortical thickness and whether measuring microstructural change with cortical MD provides additional information above and beyond cortical thickness alone.

Methods
Participants
Seventy-seven participants were recruited to a cohort study of FAD at the Dementia Research Centre, University College London: 38 with FAD mutations in either the presenilin 1 or amyloid precursor protein genes and 39 healthy controls. Of the mutation carriers, 17 had progressive cognitive symptoms and 21 were presymptomatic. All participants underwent clinical assessment, including a semi-structured interview, neurological examination and completion of the Clinical Dementia Rating scale (CDR) [15]. Estimated years to/from symptom onset (EYO) was calculated for the mutation carriers by subtracting the age at which their parent first developed progressive cognitive symptoms from the participant’s age. Blood samples were collected from all FAD family members, with mutation status assessed using Sanger sequencing.

MRI acquisition
All participants were scanned on the same 3-Tesla Siemens TIM Trio scanner using a 32-channel phased array head-coil. A sagittal 3D MP-RAGE T1-weighted volumetric MRI (echo time/repetition time/inversion time = 2.9/2200/900 ms, dimensions of 256 × 256 × 208, voxel size of 1.1 mm isotropic) was acquired. Two 64-direction DWI sequences were acquired with a single shot, spin-echo echo planar imaging (EPI) sequence (field of view 240 × 240 mm; matrix 96 × 96; yielding a voxel size of 2.5 mm isotropic; 55 contiguous axial slices; repetition time 6800 ms; echo time 91 ms; b value 1000s/mm²). We acquired nine acquisitions without diffusion weighting (b = 0 s/mm²).

Image analysis
Cortical parcellation was performed using FreeSurfer v5.30 (http://surfer.nmr.mgh.harvard.edu). The diffusion-weighted images were registered to the first b = 0 image using NiftyReg [16] and corrected for susceptibility [17], motion and eddy current distortion. The two DWI acquisitions for each participant were combined to increase the
signal-to-noise ratio, with tensor fitting performed with a single tensor model using NiftyFit [18] to produce MD maps.

We restricted our analysis to six cortical regions of interest (ROIs) identified previously as comprising the FAD cortical signature [5]: entorhinal cortex, inferior parietal cortex, precuneus, superior frontal cortex, superior parietal cortex and supramarginal cortex. The FreeSurfer label (derived from the T1-weighted acquisition) for each cortical ROI was warped from T1 to diffusion space and registered to the MD map, to allow extraction of mean MD within that region (Fig. 1). To reduce potential CSF-grey matter partial volume effects when calculating regional MD, a weighted mean was calculated. Weights were derived from interpolation of the T1 space binarised label map, which differentiated cortical grey matter from non-cortex (i.e. white matter or CSF), towards the lower resolution diffusion space. Cortical thickness for each region was calculated in FreeSurfer using the same procedure as described previously [5].

Statistical methods

The presymptomatic mutation carriers were split at the median EYO (−8.1 years) into early presymptomatic (early PS, i.e. more than 8.1 years before predicted onset) and late presymptomatic (late PS, i.e. 8.1 years or less before predicted onset), resulting in a total of four subgroups: controls; early PS; late PS; and symptomatic. Cortical MD was averaged across left and right hemispheres. For each ROI, a single linear regression was used to compare MD between the four subgroups, adjusting for age and sex. If a global test provided evidence of a main effect of group, then post hoc pairwise comparisons between sub-groups were carried out. Homoskedasticity and normality assumptions concerning residuals were checked and were not materially violated.

Given non-normal distributions and non-linear relationships, non-parametric Spearman correlation coefficients were used to assess the unadjusted association between EYO and cortical MD in each of the ROIs, first across all mutation carriers and then in presymptomatic carriers only. Spearman coefficients were also calculated to assess the association in mutation carriers between cortical MD and cortical thickness.

Additionally, in order to investigate whether MD provides additional information above cortical thickness, in mutation carriers, linear regression assessed associations between MD and EYO, after adjusting for cortical thickness. Evidence for a quadratic relationship with EYO was investigated using Wald tests. For each region, graphs were plotted to show estimated MD against EYO for a person with the study sample’s mean cortical thickness for that region. Assumptions concerning residuals were checked and were not materially violated.

All analyses used Stata v15 (StataCorp, College Station, TX, USA). No adjustments were made for multiple testing [19].

Results

Mutation carriers and controls were well matched for age (42.6 years [SD 9.5] vs 44.6 [9.5]) and sex (15 male/24 female vs 18 male/20 female). The group demographics, with mutation carriers split between symptomatic, early PS and late PS, are shown in Table 1.
Table 1 Participant demographics

|               | Controls | Early presymptomatic | Late presymptomatic | Symptomatic |
|---------------|----------|---------------------|---------------------|-------------|
| N             | 39       | 10                  | 11                  | 17          |
| Age, years (mean (SD)) | 44.6 (9.5) | 34.8 (5.5)* | 41.9 (8.4) | 47.6 (9.0) |
| Gender, m/f   | 15/24    | 3/7                 | 5/6                 | 10/7        |
| EYO, years (mean (SD)) | –       | −11.8 (2.6)      | −3.3 (4.6)          | 4.8 (4.0)*  |
| Global CDR (mean (SD)) | 0       | 0                   | 0                   | 0.85 (0.39)** |

For each ROI, there was strong evidence (p < 0.0001) for a main effect of group, so post hoc pairwise comparisons were carried out. After adjusting for age and sex, symptomatic individuals had significantly higher MD compared to controls, and to both presymptomatic groups, in all six cortical regions (p < 0.00001 for all, except in entorhinal cortex when compared with early PS (p = 0.03) and with late PS (0.0006)) (Fig. 2, Table 2, Additional file 1). Cortical MD was higher in the late PS group compared with controls across all six regions, although this reached statistical significance only in the inferior parietal cortex (estimated adjusted difference in means 0.34 mm²/s × 10⁻³, 95% CI 0.12, 0.57; p = 0.003) and the precuneus (0.28 mm²/s × 10⁻³, 0.01, 0.55, p = 0.04). No statistically significant differences in MD were found between the early PS group and controls.

When analysing the MD values, one outlier was identified (and re-checking the images found no reason to omit these data). Re-running the regression analyses without the outlier did not cause any meaningful change to the results.

Across mutation carriers (n = 36 as EYO was missing for two symptomatic participants), a positive correlation was found between cortical MD and EYO (p < 0.0001) in all regions except entorhinal cortex (p = 0.14), with MD progressively increasing over time. When including presymptomatic individuals only, the association between MD and EYO only reached formal statistical significance in the precuneus (Spearman’s rho = 0.46, p = 0.04) but a non-significant positive association was still seen in four of the five other regions. The one exception was, again, the entorhinal cortex, for which during the presymptomatic period the association between cortical MD and EYO was estimated to go in the opposite direction (Table 3).

In mutation carriers (n = 38, no missing values), cortical MD demonstrated a significant negative Spearman correlation with cortical thickness (p < 0.0001) in all ROIs except entorhinal cortex (p = 0.24) (Fig. 3). A similar negative association was found in non-carriers (rho = −0.6, p ≤ 0.0005) for all regions except entorhinal cortex and superior frontal cortex.

For comparison of age, unadjusted linear regression was used; for comparison of CDR, Fisher’s exact test was used.

EYO estimated years to onset, CDR Clinical Dementia Rating scale.

*Evidence of a difference (p < 0.05) compared with controls.

**Evidence of a difference (p < 0.001) compared with controls.

*2 missing values.
measurement of precuneus diffusivity allows differentiation between AD-MCI and controls and between AD and dementia with Lewy bodies [22, 23]. While in five of the six ROIs cortical MD was positively correlated with EYO, it was only in the precuneus that we found a significant association to persist after removing the symptomatic individuals and focusing on the presymptomatic participants only. This suggests MD in the precuneus may closely reflect disease activity in the period approaching the onset of clinical symptoms.

One previous smaller study also investigated cortical diffusivity change in presymptomatic FAD [24]. However, while they too found presymptomatic changes in the precuneus, they observed a fall in MD rather than an increase, which was felt possibly to be due to a presymptomatic inflammatory process [25]. A recent small positron emission tomography study using a tracer for brain astrocytosis appears to support the possibility of such a relationship, with astrocytic inflammation decreasing as cortical diffusivity increased [26]. A further study that

Table 2 MD values

| ROI                        | Controls Mean (SD) | Early presymptomatic Mean (SD) | Late presymptomatic Mean (SD) | Symptomatic Mean (SD) |
|----------------------------|--------------------|-------------------------------|-------------------------------|------------------------|
| Entorhinal cortex (MD SD)  | 7.43 (0.52)        | 7.73 (0.46)                   | 7.50 (0.64)                   | 8.49 (1.03)**          |
| Inferior parietal cortex (MD SD) | 7.89 (0.24)      | 7.93 (0.36)                   | 8.19 (0.26)*                  | 9.26 (0.55)**          |
| Precuneus (MD SD)          | 8.18 (0.28)        | 8.07 (0.33)                   | 8.43 (0.42)*                  | 9.50 (0.62)**          |
| Superior frontal cortex (MD SD) | 7.98 (0.28)       | 7.84 (0.22)                   | 7.99 (0.37)                   | 8.89 (0.57)**          |
| Superior parietal cortex (MD SD) | 8.34 (0.35)     | 8.32 (0.35)                   | 8.52 (0.36)                   | 9.58 (0.60)**          |
| Supramarginal cortex (MD SD) | 8.04 (0.36)       | 7.95 (0.36)                   | 8.15 (0.31)                   | 9.24 (0.62)**          |

Observed mean (SD) MD values (mm²/s × 10⁻³) are shown for each cortical ROI across the four groups. For comparison of MD, linear regression was used, adjusted for age and sex.

MD mean diffusivity

* Evidence of a difference (p < 0.05) compared with controls
** Evidence of a difference (p < 0.001) compared with controls
investigated cortical MD in presymptomatic sporadic AD (diagnosed based on measurement of CSF Aβ) reported a biphasic distribution, with those who had Aβ pathology but no evidence of neurodegeneration having reduced MD, but those with both Aβ pathology and neurodegeneration having increased MD [27]. Interestingly, however, an increase in MD in the precuneus and inferior parietal cortex—the two regions in our study to show the earliest rise—did not occur until after symptom onset. Here, in the majority of regions assessed, we found no evidence to support an initial MD reduction. The MD increase we observed across multiple regions in the late presymptomatic group, and the positive association with increasing EYO, likely indicate freer diffusion of water molecules as cellular barriers break down, consistent with what one may expect during a neurodegenerative process.

The one region in our study in which MD did not show significant correlation with disease progression across the disease spectrum was entorhinal cortex. For this region, when looking in presymptomatic individuals only, the association went in the opposite direction to all other regions, with MD progressively decreasing with increasing proximity to symptom onset. There was greater inter-individual variability in MD in the entorhinal cortex than in other regions (Fig. 2), suggesting one explanation for the discrepancy being that the small size and the anatomical location of the entorhinal cortex, which can make it more difficult to parcellate accurately, may mean its MD signal is particularly vulnerable to CSF contamination. However, it may also be that, for the presymptomatic period covered by our study, the entorhinal MD does genuinely behave differently to other regions assessed. This possibility is reflected in the linear regression model of entorhinal cortex MD as a function of EYO (adjusted for cortical thickness), which shows MD in this region initially reducing before later progressively increasing (Fig. 4). Such an initial reduction in entorhinal cortex MD would be consistent with a previous finding from two other anatomically related regions—the hippocampus and cingulum—that have also been shown to have early restriction of diffusion [28].

We found a close association between cortical MD and cortical thickness in mutation carriers for the majority of the regions assessed, with increasing cortical MD being associated with decreasing cortical thickness. Cortical thickness measurement using FreeSurfer is a widely used and well-validated method of assessing macrostructural cortical change. The association between thickness and MD therefore provides further face-validity for cortical MD being a marker of cortical integrity/degeneration, with both reduction in thickness and increasing MD likely being part of the same pathological continuum. The fact that an association was also present in healthy ageing non-carriers further supports the idea of both cortical MD and cortical thickness measuring the same general characteristic, i.e. neuronal integrity/degeneration (albeit different aspects and/or stages), which is known to progressively alter, although to a lesser extent, in healthy ageing as well as neurodegenerative disease [29, 30]. However, importantly, we found that when it comes to association with disease stage or proximity to symptom onset (as determined by EYO), cortical MD shows an association even after adjusting for cortical thickness. This suggests that, rather than providing directly analogous information to that gained from cortical thickness alone, the microscopic changes detected by measuring MD provide independent information that is of additional value and may reflect early disease-related neuronal loss. This finding is consistent with a previous study of AD that assessed whole brain cortical MD and cortical volume, which found that while cortical MD showed a trend along the trajectory from normal controls to MCI to established AD dementia, cortical volume did not demonstrate the same pattern [8]. It is also consistent with findings from another neurodegenerative disease—fronotemporal dementia—where it has been found that differences between patients and controls were greater for cortical MD than for cortical thickness, with cortical MD also showing a closer association with other measures of disease severity [31]. However, it is difficult to say at present whether the association between MD and EYO being independent of cortical thickness means MD tells us something qualitatively different about what is happening from a neurodegenerative perspective or whether it is simply a more sensitive marker of neurodegeneration. Microstructural changes such as MD may lie upstream to macrostructural thickness changes [9, 32], and so

| Region                | Correlation with EYO (Spearman’s rho) | p value |
|-----------------------|---------------------------------------|---------|
| Entorhinal cortex     | −0.43                                 | 0.05    |
| Inferior parietal cortex | 0.28                                   | 0.23    |
| Precuneus             | 0.46                                  | 0.04    |
| Superior frontal cortex | 0.40                                   | 0.07    |
| Superior parietal cortex | 0.32                                   | 0.16    |
| Supramarginal cortex  | 0.11                                  | 0.63    |

Spearman correlation coefficients and p values for the association between MD and EYO in presymptomatic mutation carriers only, in each of the six cortical regions of interest. EYO estimated years to onset.
could provide an earlier measure of change. Further studies, ideally with longitudinal assessment, will be required to confirm this.

Limitations
This study has a number of limitations. The sample size was limited by the relative rarity of FAD, although to our knowledge, this is the largest DWI study of FAD to date. As each group represents a different disease stage, their average ages differed; however, we adjusted for age in the group comparisons. Although steps were taken to minimise the effects of partial volume, with our data (not presented here) showing that the correction made led to a significant reduction in partial volume effects, this cannot be eliminated completely. Additionally, while parental age at onset has been shown to correlate closely with actual age at onset, it remains a proxy measure [3]. Finally, the current study includes cross-sectional data only, meaning that it is not possible...
directly to assess association between MD and disease progression; assessment in future longitudinal studies of whether early microstructural loss as measured by MD is associated with rate of subsequent decline will be valuable.

Conclusions
We have demonstrated that measurement of cortical MD is able to detect presymptomatic microstructural breakdown of the cerebral cortex in FAD and is associated with proximity to symptom onset independently of cortical thickness. Cortical MD may therefore provide complementary information to macrostructural atrophy. Our findings support the further investigation of cortical MD, particularly within the precuneus and inferior parietal cortex, as a potential marker of early AD neurodegeneration.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13195-020-00679-2.

Additional file 1.

Abbreviations
AD: Alzheimer’s disease; FAD: Familial Alzheimer’s disease; MRI: Magnetic resonance imaging; MD: Mean diffusivity; EYO: Estimated years to/from onset; DWI: Diffusion-weighted imaging; MCI: Mild cognitive impairment; CDR: Clinical Dementia Rating scale; ROI: Region of interest; CSF: Cerebrospinal fluid; PS: Presymptomatic

Acknowledgements
We thank the participants and their families for their generous support of this study.

Authors’ contributions
The study was conceived and designed by PSJW, IJAS and NCF. Data collection was carried out by PSJW, NSR, and YL. Processing and analysis of the imaging data was performed by ML, NT, MM and PSJW. TP and JMN led the statistical analysis. All authors contributed to interpretation of the data and preparation of the manuscript. The authors read and approved the final manuscript.

Funding
The authors would like to acknowledge support from the NIHR Queen Square Dementia BRU, the NIHR UCLH Biomedical Research Centre and the Medical Research Council (grant numbers MR/I014257/1, G0900421, G116/143) and the UK Dementia Research Institute at UCL. The Dementia Research Centre is supported by Alzheimer’s Research UK, the Brain Research Trust and The Wolfson Foundation. PSJW is funded by an MRC Clinical Research Training Fellowship (MR/M003108/1). NSR is supported by University of London Chadburn Academic Clinical Lectureship. JMS acknowledges the support of the EPSRC (EP/J020990/1), MRC (CSUB19166), ARJIK (ARUK-Network 2012-6-ICE; ARUK-PG2014-1946) and European Union’s Horizon 2020 research and innovation programme (Grant 666992). SO receives funding from the EPSRC (EP/M02533/1), EP/L016478/1, EP/K046440/1, EP/J020990/1, EP/K005278), the MRC (MR/J01107X/1) and the EU-FP7 project VPHEARE@IT (FP7-ICT-2011-9-601055). MNR and NCF are NIHR Senior Investigators (Emeritus).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study was approved by the Queen Square Research Ethics Committee (reference number 11/LO/0753) and all participants provided written informed consent.

Consent for publication
Not applicable

Competing interests
PSJW, TP, JMN, NT, IJAS, ML, MM, NSR, YL and MNR report no disclosures. JMS has received research funding from Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals and Eli Lilly and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. SO has received personal compensation for activities and research support from IXICO Ltd. He also received financial support for his research from Siemens Molecular Imaging, Mirada Medical Solution and GE Healthcare. NCF reports research support from Avid/Lilly, Biogen, Elan/Janssen, GE and Roche and has served on a data safety monitoring committee for Biogen.

Author details
1 Dementia Research Centre, UCL Institute of Neurology, Queen Square, Box 16, London WC1N 3BG, UK. 2 Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK. 3 Transitional Imaging Group, Centre for Medical Image Computing, University College London, London, UK. 4 Department of Biomedical Engineering & Imaging Sciences, King’s College London, London, UK. 5 Microstructure Imaging Group, Centre for Medical Image Computing, University College London, London, UK.

Received: 10 June 2020 Accepted: 4 September 2020
Published online: 17 September 2020

References
1. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(11):111cm33.
2. Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther. 2011;3(1).1.
3. Ruyman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253–60.
4. Dickerson BC, Bakkour A, Salat DH, Fechko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497–510.
5. Weston PS, Nicholas JM, Lehmann M, Ryan NS, Liang Y, Macpherson K, et al. Presymptomatic cortical thinning in familial Alzheimer disease: a longitudinal MRI study. Neurology. 2016;87(19):2050–7.
6. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci. 2003;4(6):469–80.
7. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Weigand SD, O’Brien PC, et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2005;64(5):902–4.
8. Scopa E, Bozzali M, Agosta F, Magnani G, Franceschi M, Sormani MP, et al. Diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up. J Neurol Neurosurg Psychiatry. 2010;81(7):796–805.
9. Ringman JM, ONeill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer’s disease mutations. Brain. 2007;130(Pt 7):1767–76.
10. Araque Caballero MA, Suarez-Calvet M, Duering M, Franzmeier M, Berzinger T, Fagan AM, et al. White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease. Brain. 2018; 141(10):3065–80.
11. Wang Q, Wang Y, Liu J, Sutphen CL, Cruchaga C, Blazey T, et al. Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer’s disease. Neuroimage Clin. 2019;22:101767.
12. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer’s disease. J Neural Transm Suppl. 1998;53:127–40.
13. Walhovd KB, Fjell AM, Amlien I, Grampaite R, Stenset V, Bjornerud A, et al. Multimodal imaging in mild cognitive impairment: metabolism, morphometry and diffusion of the temporal-parietal memory network. Neuroimage. 2009;45(1):215–23.
14. Chiapponi C, Piras F, Piras F, Fagioli S, Caltagirone C, Spalletta G. Cortical grey matter and subcortical white matter brain microstructural changes in schizophrenia are localised and age independent: a case-control diffusion tensor imaging study. PLoS One. 2013;8(10):e75115.
15. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–4.
16. Modat M, Cash DM, Daga P, Winston GP, Duncan JS, Ourselin S. Global image registration using a symmetric block-matching approach. J Medical Imaging. 2014;1(2):024003.
17. Daga P, Pendum T, Modat M, White M, Mancini L, Winston GP, et al. Susceptibility artefact correction using dynamic graph cuts: application to neurosurgery. Med Image Anal. 2014;18(7):132–42.
18. Melbourne A, Toussaint N, Owen D, Simpson I, Anthopoulos T, De Vita E, et al. NiftyFit: a software package for multi-parametric model-fitting of 4D magnetic resonance imaging data. Neuroinformatics. 2016;14(3):319–37.
19. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):46–8.
20. Rose SE, Janke AL, Chalk JB. Gray and white matter changes in Alzheimer’s disease: a diffusion tensor imaging study. J Magn Reson Imaging. 2008; 27(1):1–20.
21. Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, et al. Spatial patterns of neuroimaging biomarker change in individuals from families...
with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol. 2018;17(3):241–50.
22. Jacobs HJ, Van Bostel MP, Gronenschild EH, Uylings HB, Jolles J, Verhey FR. Decreased gray matter diffusivity: a potential early Alzheimer's disease biomarker? Alzheimer's Dement. 2013;9(1):93–7.
23. Kantarci K, Avula R, Senjem ML, Samikoglu AR, Zhang B, Weigand SD, et al. Dementia with Lewy bodies and Alzheimer disease: neurodegenerative patterns characterized by DTI. Neurology. 2010;74(22):1814–21.
24. Fortea J, Sala-Llonch R, Bartes-Faz D, Bosch B, Llado A, Bargallo N, et al. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers. J Alzheimer's Dis. 2010;22(3):909–22.
25. Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Scholl M, et al. Diverging longitudinal changes in astrogliosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain. 2016;139(Pt 3):922–36.
26. Vilaplana E, Rodriguez-Vieitez E, Ferreira D, Montal V, Almkvist O, Wall A, et al. Cortical microstructural correlates of astrogliosis in autosomal dominant Alzheimer disease. Neurology. 2020;94(19):e2026–e2036.
27. Montal V, Vilaplana E, Alcolea D, Piqueras J, Pasternak O, Gonzalez-Ortiz S, et al. Cortical microstructural changes along the Alzheimer’s disease continuum. Alzheimer’s Dement. 2017;14(3):340–51.
28. Ryan NS, Keihaninejad S, Shakespeare TJ, Lehmann M, Crutch SJ, Malone IB, et al. Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer’s disease. Brain. 2013;136(Pt 5):1399–414.
29. Scabill R, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol. 2003;60(7):989–94.
30. Benedetti B, Charil A, Rovaris M, Judica E, Valsasina P, Sormani MP, et al. Influence of aging on brain gray and white matter changes assessed by conventional, MT, and DT MRI. Neurology. 2006;66(4):535–9.
31. Ilhan-Gala I, Montal V, Borrego-Ecija S, Vilaplana E, Piqueras J, Alcolea D, et al. Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain. 2019;142(4):1121–33.
32. Muller MJ, Greverus D, Dellani PR, Weibrich C, Wille PR, Scheurich A, et al. Functional implications of hippocampal volume and diffusivity in mild cognitive impairment. NeuroImage. 2005;28(4):1033–42.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.